Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 656

1.

Markers and meaning of primary treatment failure.

Swindle PW, Kattan MW, Scardino PT.

Urol Clin North Am. 2003 May;30(2):377-401. Review.

PMID:
12735513
2.

[PSA and follow-up after treatment of prostate cancer].

Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P.

Prog Urol. 2008 Mar;18(3):137-44. doi: 10.1016/j.purol.2007.12.010. Epub 2008 Apr 18. Review. French.

PMID:
18472065
3.

The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.

Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.

J Urol. 2003 Nov;170(5):1872-6.

PMID:
14532796
4.

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.

Simmons MN, Stephenson AJ, Klein EA.

Eur Urol. 2007 May;51(5):1175-84. Epub 2007 Jan 12. Review.

PMID:
17240528
5.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
7.
8.

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.

Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.

J Nucl Med. 2009 Sep;50(9):1394-400. doi: 10.2967/jnumed.108.061507. Epub 2009 Aug 18. Erratum in: J Nucl Med. 2009 Oct;50(10):1578.

9.

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.

Pound CR, Partin AW, Epstein JI, Walsh PC.

Urol Clin North Am. 1997 May;24(2):395-406.

PMID:
9126237
10.
11.
12.

Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.

Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ.

Urology. 2004 Oct;64(4):723-8.

PMID:
15491709
13.

Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.

Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC Jr.

Urology. 2010 Feb;75(2):439-44. doi: 10.1016/j.urology.2009.06.089. Epub 2009 Oct 12.

PMID:
19819536
15.

Treatment of PSA only recurrence of prostate cancer after prior local therapy.

Moul JW.

Curr Pharm Des. 2006;12(7):785-98. Review.

PMID:
16515495
16.

Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.

Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.

Can J Urol. 2009 Oct;16(5):4813-9.

PMID:
19796456
17.
18.

Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.

Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.

J Urol. 2001 Dec;166(6):2198-201.

PMID:
11696735
19.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
20.

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.

Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.

J Urol. 2005 Dec;174(6):2191-6.

PMID:
16280762

Supplemental Content

Support Center